Sign up for the daily Inside Washington email for exclusive US coverage and analysis sent to your inbox Get our free Inside Washington email Get our free Inside Washington email Email * SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our Privacy notice
The Trump administration has reached a deal with two drug makers to lower prices of popular GLP-1 diabetes medicationsfor Americans on Medicare and Medicaid as well as for those who purchase the drugs on the administration’s forthcoming TrumpRx web site.
The deal will also see Medicare and Medicaid expand coverage for the medications to permit Americans with certain medical conditions or a Body Mass Index above certain thresholds to receive the injections as treatments for obesity and other serious maladies.
Speaking in the Oval Office on Thursday, Trump said he was “thrilled” to announce “tremendous cuts” and “drastic discounts” for the “very effective drugs,” which he referred to as “the fat drugs” and remarked that he’d “never heard anything bad” about the wildly popular medications.
“It's a triumph for American patients that will save lives and improve the health of m
Continue Reading on The Independent
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.